Sign In
Buy SOLV
$74.56
-2.00 (-2.61%)
At Close: Jun 17, 2026
Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance
04:05pm, Thursday, 27'th Feb 2025
Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3% GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41 Generated $219 million in cash from operations; fre
Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City
04:15pm, Wednesday, 26'th Feb 2025
Learn more about Solventum's long-term strategy to accelerate growth Join in person or via virtual webcast ST. PAUL, Minn.
Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports
03:37pm, Wednesday, 26'th Feb 2025
Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal repor
Trian Comments on Solventum's Sale of its Purification & Filtration Business
02:50pm, Wednesday, 26'th Feb 2025
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is t
Solventum In The Early Stages Of A Multiyear Turnaround Effort
10:16am, Tuesday, 25'th Feb 2025
Solventum In The Early Stages Of A Multiyear Turnaround Effort
Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion
08:56am, Tuesday, 25'th Feb 2025
Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion.
Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
08:39am, Tuesday, 25'th Feb 2025
Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder value Strengthens balance sheet with proceeds to be used primarily for
Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business
08:32am, Tuesday, 25'th Feb 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that the company has entered into a definitive ag
Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
08:00am, Tuesday, 11'th Feb 2025
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today ann
Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging
10:00am, Wednesday, 05'th Feb 2025
ST. PAUL, Minn. , Feb. 5, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has rank
Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025
04:05pm, Thursday, 30'th Jan 2025
Company to host an Investor Day in March 2025 ST. PAUL, Minn.
Billionaire Nelson Peltz Keeps Buying These 2 Stocks Hand Over Fist
04:28pm, Thursday, 09'th Jan 2025
Activist investor Nelson Peltz loves change. Seeking out undervalued and underperforming stocks, the billionaire often takes sizable positions in companies in a bid to unlock shareholder value via imp
Peltz's Trian Fund says 3M's Solventum spin-off not living up to potential
01:38pm, Wednesday, 08'th Jan 2025
Nelson Peltz's Trian Fund Management said in a letter to shareholders on Wednesday that medical device maker Solventum's separation from 3M has not been living up to its potential.
Trian Issues Open Letter to Solventum Shareholders
01:01pm, Wednesday, 08'th Jan 2025
Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing
06:30am, Wednesday, 08'th Jan 2025
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the org
